Now Playing
Opinion|Videos|October 30, 2025
ClipNotes: AI Built for Pharma: Why Out-of-the-Box Beats Build-From-Scratch Clip 1
Advertisement
Key moments from the Pharmaceutical Executive webcast:
- Buy the validated floor. Build only the edge.
See how leading teams are achieving measurable impact in just 90 days—without adding validation debt or manual, swivel-chair workflows. Purpose-built, inspection-ready platforms now outpace custom builds on speed, auditability, and Veeva/SFDC interoperability—driving faster adoption and tangible results.
Watch three key moments below, then
To read the full executive summary,
KEY MOMENT 1
The C-Suite Lens: When to Build vs Buy
Advertisement
Related to this article
Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Inovalon's Jen Lamppa on why inaccurate self-reported data is clinical trial enrollment's costliest problem — and how RWD fixes it.
Five major pharma stories in one day — Novo's rebrand and AI bets, Bayer's 30-year CKD first, GSK's T-cell engager, and Sanofi's portfolio exit.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
2
The Battle to Own the GLP-1 Patient Journey
3
Understanding the Latest with MFN Pricing and What It Means to Pharma
4
Novo Announces Drug Discovery Collaboration with Anthropic
5